Immunological targeting of cytomegalovirus for glioblastoma therapy
SK Nair, JH Sampson, DA Mitchell - Oncoimmunology, 2014 - Taylor & Francis
SK Nair, JH Sampson, DA Mitchell
Oncoimmunology, 2014•Taylor & FrancisHuman cytomegalovirus (CMV) is purportedly present in glioblastoma (GBM) while absent
from the normal brain, making CMV antigens potentially ideal immunological anti-GBM
targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are
capable of recognizing and killing autologous GBM tumor cells. This data supports CMV
antigen-directed immunotherapies against GBM.
from the normal brain, making CMV antigens potentially ideal immunological anti-GBM
targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are
capable of recognizing and killing autologous GBM tumor cells. This data supports CMV
antigen-directed immunotherapies against GBM.
Human cytomegalovirus (CMV) is purportedly present in glioblastoma (GBM) while absent from the normal brain, making CMV antigens potentially ideal immunological anti-GBM targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are capable of recognizing and killing autologous GBM tumor cells. This data supports CMV antigen-directed immunotherapies against GBM.
Taylor & Francis Online